Corvus Pharmaceuticals, Inc.
Status: Publicly traded
Direct answer
Corvus Pharmaceuticals, Inc. is publicly traded on NASDAQ under the ticker CRVS.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate,...
Can you invest in Corvus Pharmaceuticals, Inc.?
Yes. Corvus Pharmaceuticals, Inc. is publicly traded on NASDAQ under the ticker CRVS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Corvus Pharmaceuticals, Inc.
Detailed equity research is provided by MarketSnap.